阿尔兹海默病研究进展
Research Progress in Alzheimer’s Disease
DOI: 10.12677/acm.2024.1472138, PDF,   
作者: 张 苹*:北华大学临床医学院,吉林 吉林;李海平#:北华大学附属医院神经内科,吉林 吉林
关键词: 阿尔兹海默病发病机制治疗研究进展Alzheimer’s Disease Pathogenesis Treatment Research Progress
摘要: 阿尔茨海默病(Alzheimer’s disease,简称AD),一般被视为老年性痴呆的一种,在老年人群体中十分普遍,它是一种神经系统退化的疾病,主要影响65岁及以上的群体。在临床表现上,这种疾病主要表现为记忆丧失、语言障碍、行动能力下降、识别困难、空间定位能力受损、决策和执行能力下降,以及性格和行为的显著变化。自从AD被发现以来,大量的事实研究已经浮出水面,概述了该疾病的病因、分子机制和潜在的治疗方法,但尚未发现成功治愈该疾病的方法。这可能归因于AD的发病机制复杂,缺乏明确的分子机制,以及诊断资源和治疗的选择有限。本文就近年来关于阿尔兹海默病的病因、发病机制、临床症状及治疗策略作一综述,为进一步研究阿尔兹海默病提供理论依据。
Abstract: Alzheimer’s disease, abbreviated as AD, is generally regarded as a type of senile dementia and is very common in the elderly population. It is a neurodegenerative disease that mainly affects people aged 65 and above. In clinical manifestations, this disease is mainly characterized by memory loss, language disorders, decreased mobility, recognition difficulties, impaired spatial positioning ability, decreased decision-making and execution abilities, as well as significant changes in personality and behavior. Since the discovery of AD, a large amount of factual research has emerged, outlining the etiology, molecular mechanisms, and potential treatment methods of the disease, but no successful cure has been found yet. This may be attributed to the complex pathogenesis of AD, lack of clear molecular mechanisms, and limited diagnostic resources and treatment options. This article provides a review of the etiology, pathogenesis, clinical symptoms, and treatment strategies of Alzheimer’s disease in recent years, providing theoretical basis for further research on Alzheimer’s disease.
文章引用:张苹, 李海平. 阿尔兹海默病研究进展[J]. 临床医学进展, 2024, 14(7): 1241-1247. https://doi.org/10.12677/acm.2024.1472138

参考文献

[1] Porsteinsson, A.P., Isaacson, R.S., Knox, S., Sabbagh, M.N. and Rubino, I. (2021) Diagnosis of Early Alzheimer’s Disease: Clinical Practice in 2021. The Journal of Prevention of Alzheimers Disease, 8, 371-386. [Google Scholar] [CrossRef] [PubMed]
[2] (2023) 2023 Alzheimer’s Disease Facts and Figures. Alzheimers & Dementia, 19, 1598-1695.
[3] 王荫华, 纪勇. 世界阿尔茨海默病发展现状[J]. 中国现代神经疾病杂志, 2015, 15(7): 507-511.
[4] 黄丽, 徐英. 阿尔兹海默病患者经济负担的研究进展[J]. 成都医学院学报, 2021, 16(6): 805-808.
[5] Breijyeh, Z. and Karaman, R. (2020) Comprehensive Review on Alzheimer’s Disease: Causes and Treatment. Molecules, 25, Article No. 5789. [Google Scholar] [CrossRef] [PubMed]
[6] Zhang, X.X., Tian, Y., Wang, Z.T., et al. (2021) The Epidemiology of Alzheimer’s Disease Modifiable Risk Factors and Prevention. The Journal of Prevention of Alzheimers Disease, 8, 313-321.
[7] 刘伟, 孙彦. β-淀粉样蛋白的聚集及其调控[J]. 化工学报, 2022, 73(6): 2381-2396.
[8] Madhu, P. and Mukhopadhyay, S. (2021) Distinct Types of Amyloid-β Oligomers Displaying Diverse Neurotoxicity Mechanisms in Alzheimer’s Disease. Journal of Cellular Biochemistry, 122, 1594-1608. [Google Scholar] [CrossRef] [PubMed]
[9] Jeremic, D., Jiménez-Díaz, L. and Navarro-López, J.D. (2021) Past, Present and Future of Therapeutic Strategies against Amyloid-β Peptides in Alzheimer’s Disease: A Systematic Review. Ageing Research Reviews, 72, Article ID: 101496. [Google Scholar] [CrossRef] [PubMed]
[10] Farias, G., Cornejo, A., Jimenez, J., Guzman, L. and B. Maccioni, R. (2011) Mechanisms of Tau Self-Aggregation and Neurotoxicity. Current Alzheimer Research, 8, 608-614. [Google Scholar] [CrossRef] [PubMed]
[11] Johnson, G.V.W. and Stoothoff, W.H. (2004) Tau Phosphorylation in Neuronal Cell Function and Dysfunction. Journal of Cell Science, 117, 5721-5729. [Google Scholar] [CrossRef] [PubMed]
[12] 王金春, 刘慧影, 曹云鹏. Tau蛋白与阿尔茨海默病[J]. 中国组织工程研究, 2020, 24(17): 2775-2781.
[13] Gao, Y., Tan, L., Yu, J. and Tan, L. (2018) Tau in Alzheimer’s Disease: Mechanisms and Therapeutic Strategies. Current Alzheimer Research, 15, 283-300. [Google Scholar] [CrossRef] [PubMed]
[14] 陈付艳, 谭乔芮. 线粒体在阿尔兹海默症发病机制中的作用研究进展[J]. 医药前沿, 2019, 9(28): 5-7.
[15] Desler, C., Lillenes, M.S., Tønjum, T. and Rasmussen, L.J. (2019) The Role of Mitochondrial Dysfunction in the Progression of Alzheimer’s Disease. Current Medicinal Chemistry, 25, 5578-5587. [Google Scholar] [CrossRef] [PubMed]
[16] 刘兴博. 阿尔茨海默病与氧化应激的研究进展[J]. 母婴世界, 2018(23): 339.
[17] Bai, R., Guo, J., Ye, X., Xie, Y. and Xie, T. (2022) Oxidative Stress: The Core Pathogenesis and Mechanism of Alzheimer’s Disease. Ageing Research Reviews, 77, Article ID: 101619. [Google Scholar] [CrossRef] [PubMed]
[18] Chen, Z. and Zhong, C. (2014) Oxidative Stress in Alzheimer’s Disease. Neuroscience Bulletin, 30, 271-281. [Google Scholar] [CrossRef] [PubMed]
[19] Jaber, V.R., Zhao, Y., Sharfman, N.M., Li, W. and Lukiw, W.J. (2019) Addressing Alzheimer’s Disease (AD) Neuropathology Using Anti-Microrna (AM) Strategies. Molecular Neurobiology, 56, 8101-8108. [Google Scholar] [CrossRef] [PubMed]
[20] Wilcock, D.M. (2013) Neuroinflammatory Phenotypes and Their Roles in Alzheimer’s Disease. Neurodegenerative Diseases, 13, 183-185. [Google Scholar] [CrossRef] [PubMed]
[21] Wang, S. and Colonna, M. (2019) Microglia in Alzheimer’s Disease: A Target for Immunotherapy. Journal of Leukocyte Biology, 106, 219-227. [Google Scholar] [CrossRef] [PubMed]
[22] Sarlus, H. and Heneka, M.T. (2017) Microglia in Alzheimer’s Disease. Journal of Clinical Investigation, 127, 3240-3249. [Google Scholar] [CrossRef] [PubMed]
[23] 宋博雅. 阿尔兹海默症发病机制的研究进展[J]. 西安文理学院学报(自然科学版), 2020, 23(4): 77-79, 92.
[24] Wang, M., Zhang, H., Liang, J., Huang, J. and Chen, N. (2023) Exercise Suppresses Neuroinflammation for Alleviating Alzheimer’s Disease. Journal of Neuroinflammation, 20, Article No. 76. [Google Scholar] [CrossRef] [PubMed]
[25] Fakhoury, M. (2018) Microglia and Astrocytes in Alzheimer’s Disease: Implications for Therapy. Current Neuropharmacology, 16, 508-518. [Google Scholar] [CrossRef] [PubMed]
[26] Kalmankar, N.V., Hari, H., Sowdhamini, R. and Venkatesan, R. (2021) Disulfide-Rich Cyclic Peptides from Clitoria ternatea Protect against β-Amyloid Toxicity and Oxidative Stress in Transgenic Caenorhabditis elegans. Journal of Medicinal Chemistry, 64, 7422-7433. [Google Scholar] [CrossRef] [PubMed]
[27] Birks, J.S. and Harvey, R.J. (2018) Donepezil for Dementia Due to Alzheimer’s Disease. Cochrane Database of Systematic Reviews, 6, CD001190. [Google Scholar] [CrossRef] [PubMed]
[28] Marucci, G., Buccioni, M., Ben, D.D., Lambertucci, C., Volpini, R. and Amenta, F. (2021) Efficacy of Acetylcholinesterase Inhibitors in Alzheimer’s Disease. Neuropharmacology, 190, Article ID: 108352. [Google Scholar] [CrossRef] [PubMed]
[29] Tuszynski, M.H., Yang, J.H., Barba, D., U, H., Bakay, R.A.E., Pay, M.M., et al. (2015) Nerve Growth Factor Gene Therapy: Activation of Neuronal Responses in Alzheimer Disease. JAMA Neurology, 72, 1139-1147. [Google Scholar] [CrossRef] [PubMed]
[30] Katsouri, L., Lim, Y.M., Blondrath, K., Eleftheriadou, I., Lombardero, L., Birch, A.M., et al. (2016) PPARγ-Coactivator-1α Gene Transfer Reduces Neuronal Loss and Amyloid-β Generation by Reducing β-Secretase in an Alzheimer’s Disease Model. Proceedings of the National Academy of Sciences, 113, 12292-12297. [Google Scholar] [CrossRef] [PubMed]
[31] Rafii, M.S., Tuszynski, M.H., Thomas, R.G., Barba, D., Brewer, J.B., Rissman, R.A., et al. (2018) Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients with Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurology, 75, 834-841. [Google Scholar] [CrossRef] [PubMed]
[32] Loera-Valencia, R., Piras, A., Ismail, M.A.M., Manchanda, S., Eyjolfsdottir, H., Saido, T.C., et al. (2018) Targeting Alzheimer’s Disease with Gene and Cell Therapies. Journal of Internal Medicine, 284, 2-36. [Google Scholar] [CrossRef] [PubMed]
[33] DeMattos, R.B., Lu, J., Tang, Y., Racke, M.M., DeLong, C.A., Tzaferis, J.A., et al. (2012) A Plaque-Specific Antibody Clears Existing β-Amyloid Plaques in Alzheimer’s Disease Mice. Neuron, 76, 908-920. [Google Scholar] [CrossRef] [PubMed]
[34] Panza, F., Lozupone, M., Seripa, D. and Imbimbo, B.P. (2019) Amyloid‐β Immunotherapy for Alzheimer Disease: Is It Now a Long Shot? Annals of Neurology, 85, 303-315. [Google Scholar] [CrossRef] [PubMed]
[35] Schenk, D. (2002) Amyloid-β Immunotherapy for Alzheimer’s Disease: The End of the Beginning. Nature Reviews Neuroscience, 3, 824-828. [Google Scholar] [CrossRef] [PubMed]
[36] van Dyck, C.H. (2018) Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise. Biological Psychiatry, 83, 311-319. [Google Scholar] [CrossRef] [PubMed]
[37] Schneider, L. (2020) A Resurrection of Aducanumab for Alzheimer’s Disease. The Lancet Neurology, 19, 111-112. [Google Scholar] [CrossRef] [PubMed]
[38] Loh, J.S., Mak, W.Q., Tan, L.K.S., Ng, C.X., Chan, H.H., Yeow, S.H., et al. (2024) Microbiota-Gut-Brain Axis and Its Therapeutic Applications in Neurodegenerative Diseases. Signal Transduction and Targeted Therapy, 9, Article No. 37. [Google Scholar] [CrossRef] [PubMed]
[39] Naomi, R., Embong, H., Othman, F., Ghazi, H.F., Maruthey, N. and Bahari, H. (2021) Probiotics for Alzheimer’s Disease: A Systematic Review. Nutrients, 14, Article No. 20. [Google Scholar] [CrossRef] [PubMed]
[40] Wong, C.B., Kobayashi, Y., et al. (2018) Probiotics for Preventing Cognitive Impairment in Alzheimer’s Disease. In: Evrensel, A. and Ünsalver, B.Ö., Eds., Gut Microbiota-Brain Axis, IntechOpen, 85-104.
[41] Distrutti, E., O’Reilly, J., McDonald, C., Cipriani, S., Renga, B., Lynch, M.A., et al. (2014) Modulation of Intestinal Microbiota by the Probiotic VSL#3 Resets Brain Gene Expression and Ameliorates the Age-Related Deficit in LTP. PLOS ONE, 9, e106503. [Google Scholar] [CrossRef] [PubMed]
[42] Abraham, D., Feher, J., Scuderi, G.L., Szabo, D., Dobolyi, A., Cservenak, M., et al. (2019) Exercise and Probiotics Attenuate the Development of Alzheimer’s Disease in Transgenic Mice: Role of Microbiome. Experimental Gerontology, 115, 122-131. [Google Scholar] [CrossRef] [PubMed]
[43] Leblhuber, F., Steiner, K., Schuetz, B., Fuchs, D. and Gostner, J.M. (2018) Probiotic Supplementation in Patients with Alzheimer’s Dementia—An Explorative Intervention Study. Current Alzheimer Research, 15, 1106-1113. [Google Scholar] [CrossRef] [PubMed]